Evidence map›Paper›PMID 41446088›Full record

ArticlebioRxiv : the preprint server for biology2025

Protective and pathogenic antibody responses from a primate Shigella outbreak inform vaccine design.

Robert M Gallant, Paul Savarino, Sophia Pulido, Morgan Gilman, Ti Lu, Jennifer Hayes, Nicholas L Xerri, Torrey Williams, Mark A Ochoa, Zackary Dietz and 10 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Robert M GallantIAVI Neutralizing Antibody Center, San Diego, California, USA.ORCID 0000-0003-1741-5336
Paul SavarinoIAVI Neutralizing Antibody Center, San Diego, California, USA.
Sophia PulidoIAVI Neutralizing Antibody Center, San Diego, California, USA.
Morgan GilmanDepartment of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, Massachusetts, USA.
Ti LuBond Life Sciences Center and Department of Veterinary Pathobiology, University of Missouri, Columbia, Missouri, USA.
Jennifer HayesWisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Nicholas L XerriIAVI Neutralizing Antibody Center, San Diego, California, USA.
Torrey WilliamsIAVI Neutralizing Antibody Center, San Diego, California, USA.
Mark A OchoaIAVI Neutralizing Antibody Center, San Diego, California, USA.
Zackary DietzBond Life Sciences Center and Department of Veterinary Pathobiology, University of Missouri, Columbia, Missouri, USA.
Eric PetersonWisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Timothy ScottDepartment of Medicine, Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK.
Faye HartmannUW Veterinary Care, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Stephen G BakerDepartment of Medicine, Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK.
Robert W KaminskiLatham Biopharm Group, Cambridge, Massachusetts, USA.
Devin SokIAVI Neutralizing Antibody Center, San Diego, California, USA.
Andrew C KruseDepartment of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, Massachusetts, USA.
Wendy PickingBond Life Sciences Center and Department of Veterinary Pathobiology, University of Missouri, Columbia, Missouri, USA.
Saverio V CapuanoWisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Hayden R SchmidtIAVI Neutralizing Antibody Center, San Diego, California, USA.

Funding

WNPRC Supplemental Request for Nonhuman Primate Enclosures to Equip HIV/AIDS-Related Research FacilitiesP51OD011106 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI Dorota A. Grejner-Brzezinska · 2012 to 2026
$150.7M
EXTRAMURAL RES FACIL CONST: REPRODUCTIVE, GROWTH &DVMT, MENOPAUSEC06RR020141 · NCRR · UNIVERSITY OF WISCONSIN MADISON · PI CADWALLADER, MARTIN · 2004 to 2004
$3.6M
EXTRAMURAL REGIONAL FACILITIES CONSTRUCTIONC06RR015459 · NCRR · UNIVERSITY OF WISCONSIN MADISON · PI CADWALLADER, MARTIN · 2000 to 2000
$1.9M
NCRR NIH HHS C06 RR015459NCRR NIH HHS C06 RR020141NIH HHS P51 OD011106Wellcome Trust
6 · The paper itself

Abstract

There is currently no approved vaccine for

Identifiers

PMID41446088
PMCPMC12724442

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.